Article Text

Download PDFPDF

  1. S. Eulert1,
  2. M. Niewerth1,
  3. J. Hörstermann1,
  4. C. Sengler1,
  5. D. Windschall2,
  6. T. Kallinich3,
  7. J. Grulich-Henn4,
  8. F. Weller-Heinemann5,
  9. I. Foeldvari6,
  10. S. Hansmann7,
  11. H. Baumeister8,
  12. R. Holl9,
  13. D. Staab3,
  14. K. Minden1,3
  1. 1Deutsches Rheuma-Forschungszentrum, Programmbereich Epidemiologie, Berlin, Germany
  2. 2St. Josef-Stift Sendenhorst, Abt. für Kinder- und Jugendrheumatologie, Sendenhorst, Germany
  3. 3Charité - Universitatsmedizin Berlin, Klinik für Pädiatrie mit Schwerpunkt Pneumologie und Immunologie, Berlin, Germany
  4. 4Universitätsklinikum Heidelberg, Zentrum für Kinder- und Jugendmedizin, Heidelberg, Germany
  5. 5Klinikum Bremen-Mitte, Prof.-Hess-Kinderklinik, Bremen, Germany
  6. 6Hamburger Zentrum für Kinder- und Jugendrheumatologie, Hamburger Zentrum für Kinder- und Jugendrheumatologie, Hamburg, Germany
  7. 7Universitätsklinikum Tübingen, Klinik für Kinderheilkunde und Jugendmedizin, arcT, Tübingen, Germany
  8. 8Universität Ulm, Institut für Psychologie und Pädagogik, Ulm, Germany
  9. 9Universität Ulm, ZIBMT, Institut für Epidemiologie und med. Biometrie, Ulm, Germany


Background: Mental disorders often begin in the vulnerable phase of adolescence and young adulthood. Young people with chronic diseases are particularly at risk. Early recognition of mental health problems is necessary in order to be able to support those affected in a timely and adequate manner. By implementing a web-based generic screening tool for mental health in routine care, patients with juvenile idiopathic arthritis (JIA) and mental health conditions can be identified and provided with targeted treatment.

Objectives: To investigate the prevalence of mental health conditions in young people with JIA in routine rheumatology care.

Methods: Mental health screening is implemented as an add-on module to the National Paediatric Rheumatology Database (NPRD). The current data was gathered over a period of 24 months. Patients complete the screening tool which includes the Patient Health Questionnaire1 (PHQ-9, score 0-27) and the Generalized Anxiety Disorder scale2 (GAD-7, score 0-21) via a web-based questionnaire. The cut-off for critical values in PHQ-9 and GAD-7 were defined as values ≥ 10. Simultaneously, other data, such as sociodemographic data, disease activity (cJADAS10, score 0-30), functional status (CHAQ, score 0-3) were collected as well.

Results: The analysis included 245 patients (75% female) with a mean age of 15.7 years and a mean disease duration of 8.8 years. 38.8% of the patients had oligoarthritis (18.0% OA, persistent/20.8% OA, extended) and 23.3% RF negative polyarthritis. At the time of documentation 49 patients (30.6%) had an inactive disease (cJADAS10 ≤ 1) and 120 (49.4%) no functional limitations (CHAQ = 0). In total, 53 patients (21.6%) had screening values in either GAD-7 or PHD-9 ≥10. Patients with critical mental health screening values showed higher disease activity and more frequent functional limitations than inconspicuous patients (cJADAS10 (mean ± SD): 9.3 ± 6 vs. 4.9 ± 4.9; CHAQ: 0.66 ± 0.6 vs. 0.21 ± 0.42). When compared to males, females were significantly more likely to report either depression or anxiety symptoms (11.7% vs. 24.9%, p = 0.031).

17.6% of all patients with valid items for these data reported to receive psychological support, meaning psychotherapeutic support (14.5%) and/or drug therapy (8.6%). Among those with a critical mental health screening score, 38.7% received psychological support (psychotherapeutic support (35.5%) and/or drug therapy (16.1%)).

Conclusion: Every fifth young person with JIA reported mental health problems, however, not even every second of them stated to receive psychological support. The results show that screening for mental health problems during routine adolescent rheumatology care is necessary to provide appropriate and targeted support services to young people with a high burden of illness.

References: [1]Löwe B, Unützer J, Callahan CM, Perkins AJ, Kroenke K. Monitoring depression treatment outcomes with the patient health questionnaire-9. Med Care. 2004 Dec;42(12):1194-201.

[2]Spitzer RL, Kroenke K, Williams JB, Löwe B. A brief measure for assessing generalized anxiety disorder: the GAD-7. Arch Intern Med. 2006 May 22; 166(10):1092-7.

[3]The screening data were collected as part of COACH (Conditions in Adolescents: Implementation and Evaluation of Patient-centred Collaborative Healthcare), a project supported by the Federal Ministry of Education and Research (FKZ: 01GL1740F).

Disclosure of Interests: Sascha Eulert: None declared, Martina Niewerth: None declared, Jana Hörstermann: None declared, Claudia Sengler: None declared, Daniel Windschall: None declared, Tilmann Kallinich: None declared, Jürgen Grulich-Henn: None declared, Frank Weller-Heinemann Consultant of: Pfizer, Abbvie, Sobi, Roche, Novartis, Ivan Foeldvari Consultant of: Gilead, Novartis, Pfizer, Hexal, BMS, Sanofi, MEDAC, Sandra Hansmann: None declared, Harald Baumeister: None declared, Reinhard Holl: None declared, Doris Staab: None declared, Kirsten Minden: None declared

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.